🟢 Quantum BioPharma is trading 12.61% up in pre-market after FDA approval for Lucid-MS Phase 2

Quantum BioPharma is trading at $4.28 (+12.61%) in pre-market after FDA approval of an IND allowing Lucid-MS to advance into Phase 2.

• The randomized, placebo-controlled trial targets progressive multiple sclerosis.
• The August 14, 2026 Q2 update reported approximately US$9.5 million in combined cash, equivalents, and digital assets.
• Shares also gained 17.65% on August 14, 2026, indicating sustained upside momentum.